APLS   $40.23  135.40% Market Closed After Close 40.29 0.15%

Apellis Pharmaceuticals, Inc.
Last Events:

2023-08-09 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bearish weakening to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-08-04 Trend pattern changed from нисходящий треугольник to расходящийся клин с наклоном вниз.

2023-08-04 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: entry into the oversold zone.

2023-08-03 Trend pattern changed from канал to нисходящий треугольник.


Current temperature: 1.40
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 18
Target Price Mean 35.72
Mean unverified/preliminary 35.75 / 35.72
Target Price Low / High 18.00 / 48.00
Median / STD DEV 40.50 / 9.69
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None ActivelyBuy
rsi ActivelyBuy None None
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy None
ma50 None None None
ma100 Sell Sell ActivelyBuy
Candlestick PatternMarch 23, 2026 Bullish Harami - consists of an unusually large black body followed by a small white body contained within large black body. It is considered as a bullish pattern when preceded by a downtrend.
ISIN US03753U1060
ceo Dr. Cedric Francois M.D., Ph.D.
Website https://www.apellis.com
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.